Myocarditis Secondary to Mesalamine-Induced Cardiotoxicity in a Patient with Ulcerative Colitis

Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report

Mesalamine-containing products are often a first-line treatment for ulcerative colitis. Severe adverse reactions to these products, including cardiovascular toxicity, are rarely seen in pediatric patients. We present a case of a 16-year-old boy with ulcerative colitis treated with Asacol, a mesalamine-containing product, who developed sudden onset chest pain after four weeks on therapy. Serial ...

Acute pancreatitis secondary to topical and oral treatment with mesalamine in a patient with ulcerative colitis

Introduction: Derivatives of 5-aminosalicylic acid (5-AsA) as claversal® used for the treatment of inflammatory bowel disease may induce acute pancreatitis both orally as topically. Mesalazine is the only treatment used in our environment within the compounds of 5-AsA, due to other molecules not being available. It is available for both oral and topical, being topical form highly relevant consi...

Ulcerative colitis-induced myocarditis.

To cite: Gruenhagen B, Alraies MC, Vakil KP, et al. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/ bcr-2014-204818 DESCRIPTION A 24-year-old man presented with a 2 h history of substernal chest pain radiating to both arms with associated dyspnoea, diaphoresis and dizziness. He also reported a 3-week history of abdominal cramping with multiple loose bloody bowel move...

Title: Acute pancreatitis secondary to topical and oral treatment with mesalamine in a patient with ulcerative colitis

Mesalamine treatment mimicking relapse in a child with ulcerative colitis.

BACKGROUND There are reports on mesalamine-induced bloody diarrhea mimicking ulcerative colitis (UC) relapse, mostly in adults. METHODS Herein we present a case of a child with UC who developed relapse of hemorrhagic colitis related to mesalamine. RESULTS A 10-year-old girl developed severe symptoms mimicking UC relapse 3 weeks after introduction of mesalamine therapy. After mesalamine was ...